Taxonomic characteristics and antibiotic susceptibility of microorganisms verified in the expressed prostate secretion in post-COVID-19 patients with recurrent chronic bacterial prostatitis
- Authors: Ibishev K.S.1, Naboka Y.L.1, Ismailov R.S.1, Gudima I.А.1, Prokop Y.O.1, Vlasenko V.A.1, Kogan M.I.1
-
Affiliations:
- Rostov State Medical University
- Issue: No 6 (2023)
- Pages: 51-57
- Section: Original Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/626010
- DOI: https://doi.org/10.18565/urology.2023.6.51-57
- ID: 626010
Cite item
Open Access
Access granted
Abstract
Introduction. Recurrent chronic bacterial prostatitis (rCBP) is a hard-to diagnosis-and-treat disease which there is no consensus. A particularly difficult cohort is represented by patients who had COVID-19. The study aimed to evaluate the taxonomic structure and sensitivity to antibacterial drugs of microorganisms verified in expressed prostate secretion (EPS) in rCBP-patients who had COVID-19.
Materials and methods. A multicenter, prospective, randomized study was conducted with the inclusion of 52 rCBP patients who had COVID 19, in which the taxonomic structure and susceptibility were studied to antibacterial drugs of microorganisms that were verified and dominated in the EPS. Bacteriological study was carried out using an extended set of selective nutrient media and special cultivation conditions. Antibiotic susceptibility was determined in the taxa of microbiota dominating in the EPS.
Results. The mean age of the patients was 34.8±5.2 years, the duration of rCBP was 5.7±2.3 years. In all patients, various variants of aerobic-anaerobic compositions of microorganisms were recorded in the life cycle. A total of 27 microbiota taxa were isolated. The aerobic cluster was represented by 16 genera and/or species, the anaerobic cluster by 11. When studying antibiotic susceptibility to antibacterial drugs, an increase in antibiotic resistance of the most microorganisms isolated was revealed.
Conclusions. The taxonomic structure of microorganisms in rCBP-patients who had COVID-19 in all cases was characterized by complex and new variants of aerobic-anaerobic associations of microorganisms. When studying the antibiotic susceptibility, multi-resistant and pan-resistant bacteria were identified that is a real threat to this category of patients.
Keywords
Full Text
About the authors
Kh. S. Ibishev
Rostov State Medical University
Author for correspondence.
Email: Ibishev22@mail.ru
ORCID iD: 0000-0002-2954-842X
Ph.D., MD, Professor of the Department of Urology and Human Reproductive Health (with a course of pediatric urology and andrology)
Russian Federation, Rostov-on-DonYu. L. Naboka
Rostov State Medical University
Email: nula33@mail.ru
ORCID iD: 0000-0002-4808-7024
Ph.D., MD, professor, Head of the Department of Microbiology and Virology No.1
Russian Federation, Rostov-on-DonR. S. Ismailov
Rostov State Medical University
Email: dr.ruslan.ismailov@gmail.com
ORCID iD: 0000-0003-1958-9858
M.D., Cand.Sc.(Med); Assist.Prof., Dept. of Urology and Human Reproductive Health (withPediatric Urology and Andrology Course)
Russian Federation, Rostov-on-DonI. А. Gudima
Rostov State Medical University
Email: naguirina22@gmail.com
ORCID iD: 0000-0003-0995-7848
M.D., Dr.Sc.(Med), Assoc.prof. (Docent), prof., Dept. of Microbiology and Virology No.1
Russian Federation, Rostov-on-DonY. O. Prokop
Rostov State Medical University
Email: Unprocop@mail.ru
ORCID iD: 0000-0001-5340-9406
Post-graduate student of the department of urology and human reproductive health with the course of pediatric urology-andrology
Russian Federation, Rostov-on-DonV. A. Vlasenko
Rostov State Medical University
Email: victoriaa.vlasenko@mail.ru
ORCID iD: 0009-0009-9873-5585
5th year student of the Faculty of Medicine and Prevention
Russian Federation, Rostov-on-DonM. I. Kogan
Rostov State Medical University
Email: dept_kogan@mail.ru
ORCID iD: 0000-0002-1710-0169
Honored Scientist of the Russian Federation, Ph.D., MD, Professor, Head of the Department of Urology and Human Reproductive Health with the course of pediatric urology and andrology
Russian Federation, Rostov-on-DonReferences
- Su Z.T., Zenilman J.M., Sfanos K.S., Herati A.S. Management of Chronic Bacterial Prostatitis. Curr Urol Rep. 2020;3;21(7):29.
- Magri V., Boltri M., Cai T., Colombo R., Cuzzocrea S., De Visschere P., Giuberti R., Granatieri C.M., Latino M.A., Larganà G., Leli C., Maierna G., Marchese V., Massa E., Matteelli A., Montanari E., Morgia G., Naber K.G., Papadouli V., Perletti G., Rekleiti N., Russo G.I., Sensini A., Stamatiou K., Trinchieri A., Wagenlehner F.M.E. Multidisciplinary approach to prostatitis. Arch Ital Urol Androl. 2019;90(4):227-248.
- Kwan A.C.F., Beahm N.P. Fosfomycin for bacterial prostatitis: a review. Int J Antimicrob Agents. 2020 Oct;56(4):106106.
- Liu C.P., Chen Z.D., Ye Z.Y., He D.Y., Dang Y., Li Z.W., Wang L., Ren M., Fan Z.J., Liu H.X. Therapeutic Applications of Functional Nanomaterials for Prostatitis. Front Pharmacol. 2021;12:685465.
- Ibishev Kh.S., Kogan M.I., Magomedov R.., Krainy P.A. Modern view on the pathogenetic basis of chronic recurrent bacterial prostatitis. Effective pharmacotherapy. 2017;42:6-10. EDN ZXZAXX. Russian (Ибишев Х.С., Коган М.И., Магомедов Р.Г., Крайний П.А. Современный взгляд на патогенетические основы хронического рецидивирующего бактериального простатита. Эффективная фармакотерапия. 2017;42:6-10. EDN ZXZAXX).
- Ibishev Kh.S., Mantsov A.A, Krainy P.A. Efficiency of recombinant interferon alfa-2b in the presence of chronic recurrent bacterial prostatitis. Urologiia. 2020;4:21–26. doi: 10.18565/urology.2020.4.21–26. Russian (Ибишев Х.С. Эффективность рекомбинантного интерферона альфа-2Ь в лечении хронического рецидивирующего бактериального простатита. Х. С. Ибишев, А. А. Манцов, П. А. Крайний. Урология. 2020; 4:21-26. doi: 10.18565/urology.2020.4.21-26).
- Naboka Yu.L., Kogan M.I., Chernitskaya M.L. et al. Microbial spectrum of prostate secretion and persistence factors of bacteria found in chronic bacterial prostatitis. Bulletin of the Orenburg Scientific Center of the Ural Branch of the Russian Academy of Sciences. 2012;3:11. Russian (Набока Ю.Л., Коган М.И., Черницкая М.Л. и др. Микробный спектр секрета предстательной железы и факторы персистенции бактерий, обнаруженных при хроническом бактериальном простатите. Бюллетень Оренбургского научного центра УрО РАН. 2012;3:11).
- EAU Guidelines on Urological Infections. Edn. presented at the EAU Annual Congress Milan Italy 2021. ISBN 978-94-92671-13-4. EAU Guidelines Office, Arnhem, the Netherlands. Also available from: http:// uroweb.org/guidelines/compilations-of-all-guidelines
- Shangichev A.V., Naboka Yu.L., Ibishev Kh.S., Kogan M.I. Microbial spectrum and antibiotic sensitivity of prostate secretion microorganisms in chronic bacterial prostatitis. Kuban Scientific Medical Bulletin. 2010;3-4(117-118):207-211. Russian (Шангичев А.В., Набока Ю.Л., Ибишев X.С., Коган М.И. Микробный спектр и антибиотикочувствительность микроорганизмов секрета простаты при хроническом бактериальном простатите. Кубанский научный медицинский вестник. 2010;3-4(117-118):207-211).
- Ibishev Kh.S., Naboka Yu.L., Ferzauli A.Kh. et al. Microbiological spectrum and antibiotic sensitivity of uropathogens isolated from chronic bacterial prostatitis. Effective pharmacotherapy. 2012;39:28-30. Russian (Иби-шев Х.С., Набока Ю.Л., Ферзаули А.Х. и др. Микробиологический спектр и антибиотикочувствительность уропатогенов, выделенных при хроническом бактериальном простатите. Эффективная фармакотерапия. 2012;39:28-30).
- Zheng J., Hu R., Yang Y., Wang Y., Wang Q., Xu S., Yao P., Liu Z., Zhou J., Yang J., Bao Y., Zhang D., Shen W., Zhou Z. Antibiotic-loaded reactive oxygen species-responsive nanomedicine for effective management of chronic bacterial prostatitis. Acta Biomater. 2022;143:471-486.
- Perletti G., Marras E., Wagenlehner F.M., Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev. 2013;(8).
- Lipsky B.A., Byren I., Hoey C.T. Treatment of bacterial prostatitis. Clin Infect Dis. 2010;50(12):1641-1652.
- Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A. Post-covid complications in urology and their prevention. Urologiia. 2020;3:154-159. Russian (Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Постковидные осложнения в урологии и их профилактика. Урология. 2022;3:154-159).
- Kulchavenya E.V., Brizhatyuk E.V., Holtobin D.P., Cherednichenko A.G. A modern approach to the diagnosis of chronic prostatitis. Urologiia. 2021;2:32-39. Russian (Кульчавеня Е.В., Брижатюк Е.В., Холтобин Д.П., Чередниченко А.Г. Современный подход к диагностике хронического простатита. Урология. 2021;2:32-39).
- Krainy P.A., Ibishev H.S. Evaluation by electron microscopy of immunological disorders in the prostate secretion of patients with chronic recurrent bacterial prostatitis. Urologiia. 2021;(4):68-72 Russian (Крайний П.А., Ибишев Х.С. Оценка электронной микроскопией иммунологических нарушений в секрете предстательной железы пациентов с хроническим рецидивирующим бактериальным простатитом. Урология. 2021; 4:68-72).
- Ibishev Kh.S., Naboka Yu.L., Krainy P.A. et al. Efficacy of recombinant interferon α-2b in patients with chronic recurrent prostatitis who underwent COVID-19. Bulletin of Urology. 2022;10(4):32-42. doi: 10.21886/2308-6424-2022-10-4-32-42. Russian (Ибишев Х.С., Набока Ю.Л., Крайний П.А. и др. Эффективность рекомбинантного интерферона α-2b у пациентов с хроническим рецидивирующим простатитом, перенесших COVID-19. Вестник урологии. 2022;10(4):32-42. doi: 10.21886/2308-6424-2022-10-4-32-42).
- Kogan M.I., Ibishev Kh.S., Naboka Yu.L. et al. Extended culture study as a keypoint to rethinking antibiotic therapy for chronic bacterial prostatitis Urologiia. 2023;1:5-11. Russian (Коган М.И., Ибишев Х.С., Набока Ю.Л. и др Расширенное бактериологическое исследование как ключ к пересмотру антибактериальной терапии хронического бактериального простатита. Урология. 2023;1:5-11.
- Recommendations «Determination of the sensitivity of microorganisms to antimicrobial drugs». Version 2021-01. Russian (рекомендации «Определение чувствительности микроорганизмов к антимикробным препаратам». Версия 2021-01).
- Bader M.S., Loeb M., Leto D., Brooks A.A. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020;132(3):234-250. doi: 10.1080/00325481.2019.1680052.
- Lipsky B.A., Byren I., Hoey C.T. Treatment of bacterial prostatitis. Clin Infect Dis. 2010;50(12):1641-1652. doi: 10.1086/652861.
- Kogan M.I., Kulchavenya E.V., Kaprin A.D., et al. An open randomized study of the effectiveness of treatment of males with chronic prostatitis (categories II and IIIA) applying levofloxacin and tamsulosin combined with IndigalPlus. Russian Experimental and clinical urology. 2016;3:72-79. Russian (Коган М.И., Кульчавеня Е.В., Каприн А.Д. и др. Открытое рандомизированное сравнительное исследование эффективности терапии мужчин с хроническим простатитом категорий II и IIIA левофлоксацином и тамсулозином в комбинации с препаратом ИндигалПлюс. Экспериментальная и клиническая урология. 2016;3:72-79).
- Urinary tract infections: Molecular pathogenesis and clinical management. Eds: Mulvey M.A., Klumpp D.J., Stapleton A.E. 2016, p. 1-675.
Supplementary files
